
Revolutionizing Multiomics Research with Generative AI.
Cognit rapidly accelerates research in drug discovery and pre-clinical trials in identifying multi-omics biomarkers and fine-mapping diseases.


The current state of drug discovery is inefficient and expensive. It takes an average of 12 years and $2.6 billion to bring a new drug to market.
This is due in part to the fact that drug discovery is largely a trial-and-error process. Researchers must first identify a target gene, then develop a drug that can modulate that gene's expression. This process is often time-consuming and expensive, and it can be difficult to predict which drugs will be effective.
Combinatorial Genomics.
-
Cognit is focused on Functional, Regulatory, and Epigenomics to enable gene expression prediction and gene expression engineering.
-
The Gene expression prediction platform takes any DNA sequence (DNASE) across any cell/tissue type and eukaryotes and can predict the gene expression and transcriptomic profile of the gene.
-
Cognit's AI can predict gene expressions given mutations in distal regulatory elements that can be 1MB from the loci.
-
Cognit's perturbative oracle allows rapid CRISPR-like experiments in-silico, enabling gene expression engineering.
-
In-silico saturation mutagenesis experiments with gene knock-out and engineered mutations across introns, exons, and regulatory elements to predict gene expression.
Cognit's Gene Expression Oracle ~ Applications
-
Gene expression is useful for identifying a disease's molecular signature and correlating a pharmacodynamic marker with the dose-dependent cellular responses to the exposure to a drug.
-
Cognit is revolutionizing drug discovery, clinical development, and commercialization of new drugs through cheap, in-silico experiments.
-
Directly predicting gene expression from DNA has significant advantages in rapidly accelerating the fine-mapping of diseases.
-
Enables significant leap in saturation mutagenesis that can be conducted in-silico.
-
Significant improvements in Directed Evolution.
-
Accelerated development of de-novo Biomolecules & Protein Engineering.
Cognit Edge
The core premise of Cognit is to run self-learning models in a distributed environment to accommodate very large architectures.
-
Decentralized Intelligence to run the workload across several nodes. (approach Genomics as a Large Model Architecture).
-
Learn from Epigenetic influences which require large model architectures.
-
Ethical, Responsible AI with explainability built from ground up.
-
Self-governing AI and Math models for Autonomous modeling using distributed learning.
-
New generation Deep Learning models that work in noisy/low data settings.
-
Focused on the discovery phase (read, write, deliver) with minimal or missing data.
-
Platform focus on whole-genome and single-cell computational investigations.
-
Multimodal, multi-agent learning systems that learn from across scenarios (motifs, functions, expressions, alleles).
-
Privacy of data, transparency of decisions, and pre-emptive controls with causal inference frameworks.